<?xml version="1.0" encoding="UTF-8"?>
<p id="p0025">Important events that have occurred in the current era of regulation include the quinquennially renewed User Fee Acts, which began in 1992.
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> This was a sea change in how funding for premarket and postmarket regulatory science would be sourced, shifting from wholly congressionally budgeted funding to partially congressionally budgeted funding that is augmented by user fees obtained from regulated industries seeking market access. In fiscal year 2020, the FDA's budget is 5.94 billion USD, of which 2.67 billion USD (45%) is expected to come from user fees.
 <xref rid="bib9" ref-type="bibr">
  <sup>9</sup>
 </xref> User fee-augmented budgets have been successful in having the intended effects of facilitating product-development activities and of reducing standard NDA review times to a goal of 10 months, and priority NDA review times to a goal of 6 months. Five-year review of accompanying legislation has had the further effect of offering regularly scheduled opportunities for legislating innovation and other prospectively considered concerns, issues, and activities that might otherwise be limited to statutory remedies in response to disasters and tragedies. Similar benefits have followed the adoption of user fees for medical devices.
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref>
</p>
